Clinical Trial Results From Emerging Therapies in IgA Nephropathy
Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, review clinical trials for new and emerging treatments for IgAN, highlighting atacicept and telitacicept.
EP: 1.Disease Progression of IgA Nephropathy
EP: 2.Foundational Therapies in IgA Nephropathy
EP: 3.Interrupting Disease Progression of IgA Nephropathy
EP: 4.New Therapies in IgA Nephropathy
EP: 5.Dual Inhibition of BlyS and APRIL in IgA Nephropathy
EP: 6.Clinical Trial Results From Emerging Therapies in IgA Nephropathy
EP: 7.Use of Povetacicept in Treatment of IgA Nephropathy
EP: 8.The Future of IgA Nephropathy Treatment
This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD.
The discussion shifts to the emerging class of drugs targeting the B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) axis in IgA nephropathy (IgAN). Dr Barratt prompts Dr Rovin to share his impressions from a high-level perspective on these new therapeutics, considering the variety of drugs available, such as APRIL-only therapeutics, zigakibart, sibeprenlimab, and combinations of BAFF and APRIL inhibitors.
Dr Rovin acknowledges the challenge of assessing these drugs collectively due to variations in patient populations and study phases. However, he notes that the aggregate data suggests a beneficial effect from targeting both cytokines. His primary considerations in evaluating these drugs include efficacy, convenience, adherence, and side-effect profiles.
Dr Barratt shares his optimism about this therapeutic pathway, foreseeing its fundamental role in IgAN and its potential extension to other disease areas. He emphasizes the promising concordance in side-effect profiles and the anticipated ability to modulate these cells safely and effectively. Dr Rovin expresses agreement and expands the discussion to the broader implications of this therapeutic approach. He envisions applications beyond IgAN, including lupus and membranous nephropathy, suggesting a shift towards considering glomerular diseases as a whole rather than isolated entities. Both experts highlight the need for innovative trial designs, drawing parallels with basket trials in oncology, to explore shared pathways across various nephrological conditions, particularly in the context of rare diseases.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.
